Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.160
Open
4.160
VWAP
4.16
Vol
2.67K
Mkt Cap
10.49M
Low
4.160
Amount
11.10K
EV/EBITDA(TTM)
--
Total Shares
9.40M
EV
7.52M
EV/OCF(TTM)
--
P/S(TTM)
--
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Show More
Valuation Metrics
The current forward P/E ratio for Imunon Inc (IMNN.O) is -0.40, compared to its 5-year average forward P/E of -1.43. For a more detailed relative valuation and DCF analysis to assess Imunon Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.43
Current PE
-0.40
Overvalued PE
0.20
Undervalued PE
-3.07
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
42.75
Current PS
4.16
Overvalued PS
114.01
Undervalued PS
-28.51
Financials
Annual
Quarterly
FY2025Q3
N/A
Total Revenue
FY2025Q3
YoY :
-29.94%
-3.48M
Operating Profit
FY2025Q3
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q3
YoY :
-73.52%
-1.16
EPS - Diluted
FY2025Q3
YoY :
+9.43%
-4.44M
Free Cash Flow
FY2025Q3
N/A
Gross Profit Margin - %
FY2025Q3
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IMNN News & Events
Events Timeline
2025-11-13 (ET)
2025-11-13
07:46:23
Imunon Anticipates Sufficient Funds to Support Operations Through Q1 2026
2025-11-13
07:46:08
Imunon Announces Q3 Earnings Per Share of $1.16 Compared to $3.76 from the Previous Year
2025-11-10 (ET)
2025-11-10
07:59:42
Imunon Highlights Advancements on IMNN-001 During R&D Day
Sign Up For More Events
Sign Up For More Events
News
9.5
11-13NASDAQ.COMPinnedImunon (IMNN) Q3 2025 Earnings Conference Call Transcript
9.5
11-13NewsfilterPinnedIMUNON Releases Financial Results for Q3 2025 and Offers Business Update
1.0
11-10NewsfilterIMUNON's Public Webcast Showcases Resilience and Innovation in the Quest for the First Approved Ovarian Cancer Immunotherapy
Sign Up For More News
People Also Watch
FAQ
What is Imunon Inc (IMNN) stock price today?
The current price of IMNN is 4.16 USD — it has increased 0 % in the last trading day.
What is Imunon Inc (IMNN)'s business?
What is the price predicton of IMNN Stock?
What is Imunon Inc (IMNN)'s revenue for the last quarter?
What is Imunon Inc (IMNN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Imunon Inc (IMNN)'s fundamentals?
How many employees does Imunon Inc (IMNN). have?